Cellectis To Reveal Data On TALE-Based Editors And Non-Viral Gene Therapies At The 31st Annual ESGCT Congress
Portfolio Pulse from Benzinga Newsdesk
Cellectis, a clinical-stage biotechnology company, will present pre-clinical data on TALE-based editors and non-viral gene therapies at the 31st Annual ESGCT Congress in October 2024.
October 22, 2024 | 6:34 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cellectis will present new data on TALE-based editors and non-viral gene therapies, potentially enhancing its position in the gene-editing market.
The announcement of new data on TALE-based editors and non-viral gene therapies could enhance Cellectis's market position and attract investor interest, potentially leading to a positive short-term impact on its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90